Antiganglioside antibodies and electrodiagnosis at the first exam in patients with Guillain–Barré syndrome
| Antiganglioside antibody* | p Value | |||
| Positive (n=37) | Negative (n=66) | Total (n=103) | ||
| Japanese patients (n=103) | ||||
| AIDP | 11 (30%) | 27 (41%) | 38 (37%) | NS |
| AMAN | 15 (41%) | 9 (14%) | 24 (23%) | 0.002 |
| Unclassified | 11 (30%) | 30 (45%) | 41 (40%) | NS |
| Antiganglioside antibody* | p Value | |||
| Positive (n=19) | Negative (n=34) | Total (n=53) | ||
| Italian patients (n=53) | ||||
| AIDP | 5 (26%) | 26 (76%) | 31 (58%) | 0.0004 |
| AMAN | 7 (37%) | 2 (6%) | 9 (17%) | 0.004 |
| Unclassified | 7 (37%) | 6 (18%) | 13 (25%) | NS |
Date are expressed as number (%).
↵* IgG antibodies against GM1, GM1b, GD1a, GD1b or GalNAc-GD1a.
AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; NS, not significant.